OTCMKTS:WINT - Windtree Therapeutics Stock Price, News & Analysis

$4.01
0.00 (0.00 %)
(As of 09/18/2019 08:00 AM ET)
Today's Range
$4.01
Now: $4.01
$4.01
50-Day Range
$3.60
MA: $3.94
$4.15
52-Week Range
$2.05
Now: $4.01
$5.35
Volume100 shs
Average Volume1,729 shs
Market Capitalization$129.08 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.04
Windtree Therapeutics, Inc, a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:WINT
Previous SymbolNASDAQ:WINT
CUSIP25466840
Phone215-488-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.79 million
Book Value$17.45 per share

Profitability

Net Income$-20,530,000.00
Net Margins-3,548.97%

Miscellaneous

Employees27
Market Cap$129.08 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.


Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics Inc (OTCMKTS:WINT) posted its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.20) EPS for the quarter. The biotechnology company had revenue of $0.16 million for the quarter. Windtree Therapeutics had a negative return on equity of 65.66% and a negative net margin of 3,548.97%. View Windtree Therapeutics' Earnings History.

When is Windtree Therapeutics' next earnings date?

Windtree Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Windtree Therapeutics.

Has Windtree Therapeutics been receiving favorable news coverage?

Media headlines about WINT stock have been trending negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Windtree Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Windtree Therapeutics.

Who are some of Windtree Therapeutics' key competitors?

What other stocks do shareholders of Windtree Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Windtree Therapeutics investors own include La Jolla Pharmaceutical (LJPC), Trevena (TRVN), XOMA (XOMA), CTI BioPharma (CTIC), Reshape Lifesciences (RSLS), SLS International (SLS), Microbot Medical (MBOT), Novavax (NVAX), CorMedix (CRMD) and Alliqua Biomedical (ALQA).

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the folowing people:
  • Mr. Craig E. Fraser, Pres, CEO & Director (Age 54)
  • Mr. John A. Tattory, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 60)
  • Mr. George Cox, VP of Manufacturing & Supply Chain and Technical Operations (Age 67)
  • Ms. Mary B. Templeton, Sr. VP, Gen. Counsel & Corp. Sec. (Age 72)

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $4.01.

How big of a company is Windtree Therapeutics?

Windtree Therapeutics has a market capitalization of $129.08 million and generates $1.79 million in revenue each year. Windtree Therapeutics employs 27 workers across the globe.View Additional Information About Windtree Therapeutics.

What is Windtree Therapeutics' official website?

The official website for Windtree Therapeutics is http://www.windtreetx.com/.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]


MarketBeat Community Rating for Windtree Therapeutics (OTCMKTS WINT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe WINT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WINT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2019 by MarketBeat.com Staff

Featured Article: Stop Order

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel